Mechanistic description
Specific commensal bacteria activate vagal afferent neurons through GLP-1 receptor signaling, promoting neuroprotective pathways in the brainstem and substantia nigra. Targeted vagal stimulation combined with GLP-1 receptor agonists could enhance endogenous neuroprotection.
Evidence for (5)
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1.
Dissociable hindbrain GLP1R circuits for satiety and aversion.
Brainstem BDNF neurons are downstream of GFRAL/GLP1R signalling.
Association of semaglutide with risk of suicidal ideation in a real-world cohort.
Evidence against (2)
A phase 3 exenatide Parkinson trial tested GLP-1 receptor agonism as disease modification, providing a direct translational stress test for GLP-1 neuroprotection.
A Cochrane review found the clinical evidence base for GLP-1 receptor agonists in Parkinson disease was limited, cautioning against strong efficacy claims.